Hepatocellular carcinoma (HCC) is one of the most common malignant tumors. During the recent years, external-beam radiation therapy (EBRT) has been safely and effectively employed for the management of HCC. We overviewed the current evidence regarding the efficacy and safety of EBRT for HCC according to the different target population. PubMed database was searched for identifying English-language full-text articles regarding EBRT for the treatment of HCC. Search items were "hepatocellular carcinoma AND radiation therapy". Until now, preliminary evidence has suggested the following role of EBRT for HCC. 1) EBRT, especially stereotactic body radiation therapy, is an emerging choice of therapy for small HCC. 2) EBRT combined with non-surgical treatment can achieve an excellent intrahepatic tumor control and a potential survival benefit for huge HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies (1) . Treatment selection and prognostic assessment of HCC often depends on the tumor stage, performance status, and severity of liver dysfunction. Currently, there are lots of staging systems for HCC (2) (3) (4) . Barcelona Clinic Liver Cancer (BCLC) staging system may be the most commonly used system for the management of HCC. According to the BCLC staging system, liver transplantation, surgical resection, and local ablative therapies, such as percutaneous ethanol injection or radiofrequency ablation (RFA), are recommended in the treatment of BCLC stage 0 or A HCC; transarterial chemoembolization (TACE) is recommended in the treatment of BCLC stage B HCC; and sorafenib is recommended in the treatment of BCLC stage C HCC (5) . Except for the common therapeutic strategies, lots of novel therapeutic modalities have been widely explored (6, 7) .
Radiation therapy is a major traditional anticancer modality for solid tumors along with surgery and chemotherapy. In the past, the role of radiation therapy was very limited in the treatment of HCC due to the poor tolerance and low radiosensitivity of liver. Nowadays, internal radiation therapy, such as radioembolization, has been increasingly recognized for the management of HCC (8, 9) . By comparison, the role of external-beam radiation therapy (EBRT) needs further confirmation in HCC patients. Recently, the 2014 Korean Practice Guideline suggests that EBRT can be considered if patients have preserved liver function (i.e., ChildPugh class A or superb B), are not eligible for major treatments, have an incomplete response to TACE, or have portal vein invasion when the percentage of irradiated total liver volume receiving ≥ 30 Gy is ≤ 60% there is a demand for alleviating the symptoms caused by primary HCC or its metastases (10).
Modern EBRT has been employed for the management of HCC, which can deliver a higher radiation dose to the tumor more precisely and produce a lower risk of EBRT-induced liver disease (RILD) (11) . More notably, EBRT can result in a high local tumor control rate of 70.0-100.0% in HCC patients (12, 13) . Considering a promising role of EBRT alone and in combination with other therapies for HCC, this paper aimed to overview the current evidence regarding the efficacy and safety of EBRT for HCC according to the different target population.
EBRT approaches
Modern EBRT approaches include 3-dimensional conformal radiation therapy (3D-CRT), intensitymodulated radiation therapy (IMRT), stereotactic ablative body radiation therapy (SBRT), and imageguided radiation therapy. Three major EBRT approaches are reviewed in details as follows.
3D-CRT
In contrast to the conventional 2D-RT technique, 3D-CRT uses multiple coplanar or non-coplanar fields in order to reduce the high-dose exposure of normal tissues including the liver and bowels and to increase the tumor dose coverage. With the use of CT images for RT planning and a computerized treatment planning system, the tumor and surrounding normal liver can be accurately delineated, and the delivered dose and irradiated volume of the tumor and normal liver can be precisely evaluated. However, the risk of RILD remains high, especially in patients with Child-Pugh class B or C, prior TACE, portal vein invasion, and hepatitis B carrier status (14, 15) . Considering that these risk factors are unavoidable in patients undergoing CRT, 3D-CRT is useful to overcome these obstacles and improve the clinical outcomes in terms of tumor control and normal tissue toxicity.
IMRT
IMRT is an advanced form of conformal RT that facilitates the delivery of a higher radiation dose as compared to 3D-CRT. A computer-aided automated optimization process, known as inverse treatment planning, modulates the intensity of each beam to gain the desired target coverage while minimizing the dose to the normal organs. IMRT has the potential of dose escalation for HCC without an increased risk of RILD as compared to 3D-CRT, which signals the potential for improved survival and quality of life in HCC patients (15, 16) . However, there is no standard technique for IMRT delivery and the IMRT plan is not always better than the 3D-CRT plan.
SBRT
SBRT is generally defined as a treatment modality
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months and the 1-year overall survival rate was 32.3%.
EBRT vs. resection
In a Chinese comparative study, Su et al. (22) found that the local effect of SBRT was similar to that of surgical resection in small HCC patients with 1 or 2 nodules and Child-Pugh A cirrhosis. SBRT was less invasive and had fewer adverse effects than resection. Notably, a propensity score-matching analysis demonstrated that the 1-, 3-, and 5-year overall survival rates were statistically similar between HCC patients undergoing SBRT and those undergoing surgical resection (100%, 91.8%, and 74.3% vs. 96.7%, 89.3%, and 69.2%, respectively).
EBRT vs. RFA
Two studies compared the outcomes of SBRT vs. RFA for patients with small HCC. Wahl et al. (23) found that the time freedom from local progression was not significantly different between patients with HCC ≤ 2 cm undergoing SBRT and those undergoing RFA. The patients undergoing SBRT had lower pretreatment Child-Pugh scores and higher pretreatment alphafetoprote in levels and were submitted to more liverdirected treatments. No SBRT procedure-related death was reported. The rate of late toxicities was similar between the two groups. Seo et al. (24) also conducted a Markov model-based analysis and found a similar median survival time between patients with HCC ≤ 3 cm undergoing SBRT and those undergoing RFA (76.5 months vs. 77.4 months). The 5-year overall survival rate was 61.1% and 58.5% in SBRT and RFA groups, respectively.
EBRT plus TACE vs. TACE alone
In a Japanese study, Honda et al. (25) suggested that SBRT in combination with TACE should be effective for the treatment of hypervascular small HCC (≤ 3 cm). No acute toxicities were fatal. No RILD developed. In the combination therapy group, the 1-and 3-year overall survival rates were both 100.0%. By comparison, in the TACE alone group, the 1-, 2-, and 3-year overall survival rates were 88.9%, 73.6%, and 66.1%, respectively.
EBRT for huge HCC
In huge HCC (i.e., tumor diameter ≥ 10 cm), microvascular invasion is more common and tumor grade is higher (26 (27, 28) . However, the 5-year overall survival rate of huge HCC treated with TACE is less than 10.0% (29) . Additionally, the subgroup analysis for delivering a high dose of radiation to the target in a few fractions (typically 1-5 fractions) with a high degree of precision. SBRT with a common linear accelerator usually utilizes multiple coplanar or noncoplanar static beams or multiple arc beams. To irradiate the tumor more accurately and to increase the sparing of the normal organs, SBRT is performed in combination with at least one kind of image-guided RT technique integrated into the treatment machine. During the last decade, the use of SBRT for HCC has increased substantially and the practice guidelines recommend SBRT as an alternative to the ablation/ embolization techniques, or when they have failed or are contraindicated (10). Generally, SBRT was used for the treatment of multiple small HCCs (< 5-6 cm) in patients with Child-Pugh class A or B.
Literature search
PubMed database was searched for identifying Englishlanguage full-text articles regarding EBRT for the treatment of HCC. Search items were "hepatocellular carcinoma AND radiation therapy". (17) . Only four studies provided the data regarding the grade of adverse events in patients treated with EBRT in Table 2B . Tables  3A and B summarized the study quality.
Major findings

EBRT for small HCC
Surgical resection and LT are the first-line curative treatment options for small HCC (5). However, surgery is often contraindicated in HCC patients with poor liver function. EBRT, especially SBRT, becomes an emerging alternative for small HCC. Studies demonstrated that the tumor control rate of EBRT for small HCC was 89.9-100% and that the 1-and 3-year overall survival rates were 86.0-95.0% and 53.8-70.0%, respectively. Additionally, no RILD was reported, few adverse effects were observed, and the prevalence of grade III toxicity was 0-23.0% (18) (19) (20) .
EBRT for patients with poor liver function
In a Canadian prospective study, Culleton et al. (21) performed SBRT in patients with Child-Pugh class B or C small HCC. None had any tumor progression at the irradiated site of HCC. Most of adverse effects after SBRT were grade I/II. The median survival time was 7.9 (2015) Culleton (2014) Su (2017) Wahl (2016) Seo (2016) Honda (2013) Que (2014) Han (2014) Guo (2000) Kim (2014) Zeng (2005) Tang (2013) Yoon (2012) Yu (2017) Lu (2015) Jiang (2012) Sun (2016) Casamassima (2012) Zhou (2014) Park (2015) He ( Moore (2017) Andolino (2011) Yu (2014) Wang (2015) Bai ( Table 3B . Quality assessment of prospective studies using Newcastle Ottawa Scale Author (year)
Culleton (2014) Yu (2017) Yu (2014) Representativeness of the exposed cohort 1 point 1 point 1 point
Note: Study quality was assessed as follows: low quality = 0-4; high quality = 5-8.
Selection of the non-exposed cohort Note: Study quality was assessed as follows: low quality = 0-4; high quality = 5-8.
Selection of the non-exposed cohort 
EBRT plus TACE
Between 1989 and 1998, Guo and Yu (33) treated 107 unresectable huge HCC patients with TACE followed by EBRT. Most of side effects occurred after TACE and were transient, and the overall 3-month response rate was 48.6%. The median survival time was 18.0 months. The 1-, 3-, and 5-year overall survival rates were 59.4%, 28.4%, and 15.8%, respectively.
EBRT plus TACE vs. TACE alone
Kim et al. (34) compared the outcomes of patients with EBRT after TACE vs. TACE alone. This combination therapy had significantly superior progression-free survival, intrahepatic control, and overall survival than TACE alone.
EBRT for HCC with portal vein tumor thrombosis (PVTT)
Although sorafenib is the first-line treatment option for advanced HCC, its efficacy in HCC patients with PVTT is frequently questioned (35) . Additionally, PVTT can lead to the reduction of hepatic blood supply and development of severe portal hypertension related complications, such as gastroesophageal variceal bleeding and ascites (36) , which limits the selection of treatment options. Very localized HCC accompanied by PVTT in patients with preserved hepatic function can be surgically resected (37, 38) . However, surgical removal of tumor thrombus is rarely performed probably owing to the limited hepatic reserve (39) . TACE may be performed safely in HCC patients with PVTT (40), but its efficacy is unsatisfactory (41) . Recently, EBRT has been used as an alternative treatment for HCC with PVTT achieving a high response rate.
EBRT vs. TACE or resection
In Both studies suggested a superiority of 3D-CRT over TACE/resection for HCC with PVTT.
EBRT plus TACE
In 2012, Yoon et al. (44) analyzed 412 patients treated with 3D-CRT after TACE for HCC and PVTT. Acute toxicities were mostly mild, such as fatigue, anorexia, and nausea. The objective response rate was 27.9% (complete response rate: 3.6% and partial response rate: 24.3%). The median survival time was 10.6 months. The 1-and 2-year overall survival rates were 42.5% and 22.8%, respectively. Additionally, in 2017, Yu et al. (45) reported the safety and efficacy of TACE followed by 3D-CRT in such patients. The median follow-up time was 11.4 months. Liver function status was not significantly worsened after treatment. The 3-month objective response rate at the radiation therapy targeted area was 69.6%. The 2-year overall survival, recurrencefree survival, and progression-free survival rates were 62.9%, 47.6%, and 14.3%, respectively.
EBRT plus TACE vs. TACE alone
In 2015, Lu et al. (46) compared the outcomes of 3D-CRT plus TACE vs. TACE alone. No serious adverse reactions requiring treatment were reported. In the combination treatment group, the median survival time was 13.0 months; and the 1-and 2-year overall survival rates were 62.4% and 20.8%, respectively. By comparison, in the TACE alone group, the median survival time was 9.0 months; and the 1-and 2-year overall survival rates were 56.5% and 18.8%, respectively. The overall survival was statistically significant between the two groups (P = 0.047). Thus, compared with TACE alone, the combination treatment might improve the survival of HCC patients with PVTT.
EBRT for HCC with extrahepatic metastases
Currently, extrahepatic metastases can be frequently observed due to the prolonged survival of advanced HCC patients. The most common metastatic organ from HCC was the lung followed by adrenal gland, brain, bone, and lymph node, etc. (47) (48) (49) (50) . Unfortunately, there is no standard treatment for HCC with extrahepatic metastases. Although the resection of isolated metastatic lesions from some malignancies may provide a survival benefit, its role for extrahepatic metastases from HCC is not well-established (51) . Recently, EBRT has been used as a palliative treatment to relieve the pain and improve the quality of life in HCC patients with extrahepatic diseases, thereby leading to a satisfactory treatment response.
Lung metastases
EBRT alone
Jiang et al. (52) indicated a pronounced efficacy of EBRT for lung metastases. A total of 13 patients with lung metastases from HCC underwent EBRT. Adverse effects were mild. The median progression-free survival time was 13.4 months. The 2-year survival rate was 70.7%.
EBRT alone vs. EBRT plus sorafenib
Sun et al. (53) compared the outcomes of IMRT alone vs. IMRT combined with sorafenib for the treatment of 45 HCC patients with lung metastases. In the IMRT alone group, only one case developed anorexia. In the combination treatment group, most of the toxicities were mild and related to sorafenib. The 1-and 2-year overall survival rates were 66.8% and 30.4% vs. 91.1% and 78.8% in IMRT alone and IMRT plus sorafenib groups, respectively. Thus, EBRT plus sorafenib may be a more promising approach in such patients. 
Adrenal metastases
Brain metastases
The prognosis of HCC patients who developed brain metastases is extremely poor, with a reported median survival time of 1.0-3.0 months (56, 57) . Park et al. (58) treated 97 patients with brain metastases from HCC by EBRT alone or after surgery and/or radiosurgery. The median survival time was 3.5 months, which was superior to the previous data (56, 57) . The whole brain radiation therapy may be a choice of treatment for brain metastases.
Bone metastases
Bone metastases are a common cause of pain in metastatic HCC. EBRT has been reported to be effective in palliating painful bone metastases with a partial pain relief rate of 80.0-90.0% and a complete pain relief rate of 50.0% (59) . The 1-and 2-year overall survival rates were 32.4% and 13.2%, respectively (60) . The median survival time of patients treated with EBRT for bone metastases from HCC was 5.0-7.4 months (60) (61) (62) . A large cohort of HCC patients with bone metastases treated with EBRT suggested that acute EBRT-associated toxicities were mild or absent (60) . Therefore, palliative EBRT might be considered for bone metastases from HCC.
Lymph node metastases
Since HCC invasions are mostly hematogenous, lymph node metastases are uncommon. The incidence of lymph node involvement in HCC patients treated with surgery was reportedly 5.1-7.5% (63), but the incidence from an autopsy series was 25. 
EBRT as a bridge to LT for HCC
LT represents the best treatment option for selected HCC (67) . However, the use of LT is limited by the shortage of donor organs. Many patients need a long waiting time on the transplant list and may drop out because of tumor progression (68) . According to the American Association for the Study of Liver Diseases guidelines regarding the management of HCC, bridging therapies should be applied if the waiting time is longer than 6 months (69). Local treatment as a bridge to LT has been utilized to minimize the tumor progression and reduce the post-transplant recurrence. TACE and RFA are the most common bridging therapies, but generally recommended for only patients with well-compensated cirrhosis (5) . Recent studies suggested the potential role of EBRT in such patients. EBRT might be an effective bridging therapy for HCC patients awaiting LT, which may provide an excellent local control with minimal side effects, downsize or stabilize tumors prior to LT, and achieve a good pathological response. 
EBRT as a bridge to LT
Postoperative EBRT
Surgical resection is technically difficult for centrally located HCC (75) and HCC located close to the major vessels (76) . In such patients, postoperative EBRT might be potentially useful.
Postoperative EBRT for centrally located HCC
A study by Yu et al. (77) evaluated the role of 3D-CRT after narrow-margin resection for centrally located HCC. Fifty-eight of 119 patients were treated with postoperative 3D-CRT. No RILD occurred. Notably, in the subgroup analysis, postoperative 3D-CRT significantly improved the recurrence-free survival of patients with small HCC (≤ 5 cm), but not the overall survival.
Postoperative EBRT for HCC located close to the major vessels
In an exploratory study, Wang et al. (78) treated 116 HCC patients located close to the major vessels by narrow-margin (< 1.0 cm) resection. Among them, 33 patients received postoperative IMRT and 83 did not receive IMRT. During a median follow-up time of 33.0 months, the observed toxicities were mild and no patient developed any RILD. Patients receiving narrow-margin resection plus IMRT had a significantly lower incidence of early recurrence than those receiving narrow-margin resection alone. The 3-year overall survival and diseasefree survival rates of narrow-margin resection plus postoperative IMRT were significantly superior to those of narrow-margin resection alone. Additionally, the overall survival and disease-free survival rates of narrowmargin resection plus postoperative IMRT were similar to those of wide-margin resection. 
Conclusions
Based on the current evidence, EBRT should be considered in the following conditions. First, EBRT should be a potential alternative choice of therapy for small HCC, especially if the tumor was unresectable. Second, EBRT should be considered for relieving the pain for patients with extrahepatic metastases, especially the bone pain. Third, adjunctive EBRT may be considered in patients with huge HCC, HCC patients with PVTT, HCC patients awaiting LT, and HCC patients treated with resection. However, the role of EBRT remains limited due to the relatively low level of evidence. A majority of studies were retrospective (n = 33), and a minority of studies were prospective (n = 3). No randomized controlled trial regarding EBRT was performed. Additionally, most of evidence was from Eastern countries. Thus, high-quality clinical trials should be needed to further establish the status of EBRT for the treatment of HCC.
